Search research articles
Contact Us
Filters
Showing results (111-120 of 208) with videos related to
Page
of 21
Sort By:
Cancer Chemotherapy and Pharmacology
|
May 4, 2018
Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer
Egbert F Smit, Edward B Garon, Martin Reck, et al.
Clinical Lung Cancer
|
January 1, 2025
Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy
Omar Elghawy, Adam Barsouk, Lauren Reed-Guy, et al.
JAMA Otolaryngology-- Head & Neck Surgery
|
June 23, 2022
Association Between Up-front Surgery and Risk of Stroke in US Veterans With Oropharyngeal Carcinoma
Lova Sun, Robert Brody, Danielle Candelieri, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 2, 2008
Promising survival in patients with recurrent non-small cell lung cancer treated with docetaxel and gemcitabine in combination as second-line therapy
Chao Hui Huang, Michael M Millenson, Eric J Sherman, et al.
The Lancet. Oncology
|
November 10, 2009
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
James A Bonner, Paul M Harari, Jordi Giralt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 15, 2009
A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors
Roger B Cohen, Suzanne F Jones, Charu Aggarwal, et al.
JCO Precision Oncology
|
August 21, 2019
Impact of <i>KRAS</i> and <i>TP53</i> Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With <i>STK11</i>-Mutated Advanced Non-Small-Cell Lung Cancer
Erin Bange, Melina E Marmarelis, Wei-Ting Hwang, et al.
Investigational New Drugs
|
September 18, 2015
Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors
Sandrine J Faivre, Anthony J Olszanski, Karin Weigang-Köhler, et al.
Cardio-Oncology (London, England)
|
March 31, 2021
Treatment of corticosteroid refractory immune checkpoint inhibitor myocarditis with Infliximab: a case series
Robert S Zhang, Allison Padegimas, Kathleen M Murphy, et al.
JTO Clinical and Research Reports
|
August 11, 2025
Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLC
Omar Elghawy, Adam Barsouk, Jonathan H Sussman, et al.
Page
of 21
Search research articles
Search
Showing results (111-120 of 208) with videos related to
Sort By:
Page
of 21
Cancer Chemotherapy and Pharmacology
|
May 4, 2018
Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer
Egbert F Smit, Edward B Garon, Martin Reck, et al.
Clinical Lung Cancer
|
January 1, 2025
Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy
Omar Elghawy, Adam Barsouk, Lauren Reed-Guy, et al.
JAMA Otolaryngology-- Head & Neck Surgery
|
June 23, 2022
Association Between Up-front Surgery and Risk of Stroke in US Veterans With Oropharyngeal Carcinoma
Lova Sun, Robert Brody, Danielle Candelieri, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 2, 2008
Promising survival in patients with recurrent non-small cell lung cancer treated with docetaxel and gemcitabine in combination as second-line therapy
Chao Hui Huang, Michael M Millenson, Eric J Sherman, et al.
The Lancet. Oncology
|
November 10, 2009
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
James A Bonner, Paul M Harari, Jordi Giralt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 15, 2009
A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors
Roger B Cohen, Suzanne F Jones, Charu Aggarwal, et al.
JCO Precision Oncology
|
August 21, 2019
Impact of <i>KRAS</i> and <i>TP53</i> Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With <i>STK11</i>-Mutated Advanced Non-Small-Cell Lung Cancer
Erin Bange, Melina E Marmarelis, Wei-Ting Hwang, et al.
Investigational New Drugs
|
September 18, 2015
Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors
Sandrine J Faivre, Anthony J Olszanski, Karin Weigang-Köhler, et al.
Cardio-Oncology (London, England)
|
March 31, 2021
Treatment of corticosteroid refractory immune checkpoint inhibitor myocarditis with Infliximab: a case series
Robert S Zhang, Allison Padegimas, Kathleen M Murphy, et al.
JTO Clinical and Research Reports
|
August 11, 2025
Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLC
Omar Elghawy, Adam Barsouk, Jonathan H Sussman, et al.
Page
of 21